Compile Data Set for Download or QSAR
Report error Found 140 Enz. Inhib. hit(s) with all data for entry = 9392
TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392540(N4-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-(...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392541(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-3-(a...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392538(4-amino-N-((6-amino-2,4- dimethylpyridin-3-yl)meth...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392539(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392536(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392537(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392534(5-amino-N-((6-amino-2,4- dimethylpyridin-3-yl)meth...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392535(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-2-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392532(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392533(4-acetamido-N-((6-amino-2,4- dimethylpyridin-3-yl)...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392530(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392531(3-amino-N-((6-amino-2,4- dimethylpyridin-3-yl)meth...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392527(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392525(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392526(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392552(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392553(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392550(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392551(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-2-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392548(4-amino-N-((6-amino-2,4- dimethylpyridin-3-yl)meth...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392549(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392546(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-7-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392544(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-5-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392545(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-5-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392542(2-amino-N-((6-amino-2,4- dimethylpyridin-3-yl)meth...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392543(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-2-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392572(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392573(N-((1-aminoisoquinolin-6-yl)methyl)- 1-((3-chloro-...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392570(N-((3-chloro-1H-pyrrolo[2,3- b]pyridin-5-yl)methyl...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392568(N-((1-aminoisoquinolin-6-yl)methyl)- 1-((3-chloro-...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392566(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392567(N-((3-chloro-6-fluoro-1H-indol-5- yl)methyl)-1-((3...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392563(N-((1-aminoisoquinolin-6-yl)methyl)- 1-((3-chloroq...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392588(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-5-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392589(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392586(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-3-cy...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392587(N-((6-amino-2-methylpyridin-3- yl)methyl)-3-cyano-...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392585(6-((4-(((6-amino-2,4-dimethylpyridin- 3-yl)methyl)...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392582(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392581(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392578(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-3-cy...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392579(N-((6-amino-2-methylpyridin-3- yl)methyl)-3-cyano-...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392576(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-3-cy...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392574(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392575(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-3-cy...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392604(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392605(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-1-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392602(US10301284, Example 114 | N-((6-amino-2,4-dimethyl...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392603(N-((6-amino-2-methylpyridin-3- yl)methyl)-2-((3-ch...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

TargetPlasma kallikrein(Human)
Attune Pharmaceuticals

US Patent
LigandPNGBDBM392600(N-((6-amino-2,4-dimethylpyridin-3- yl)methyl)-2-((...)
Affinity DataIC50: 100nMAssay Description:A 10 mM solution of the test compound was made in DMSO. This solution was serially diluted 1:5 in DMSO to yield 2000, 400, 80, 16, 3.2, 0.64, 0.128, ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/3/2021
Entry Details
US Patent

Displayed 1 to 50 (of 140 total ) | Next | Last >>
Jump to: